Lanadelumab (KLKB1) - Research Grid Biosimilar
Gecertificeerd

Lanadelumab (KLKB1) - Research Grid Biosimilar

Catalog #: 10-771
Maat: 0.1 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Background

Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials.Lanadelumab was developed by Shire and FDA approved on August 28, 2018.5.

Immunogen

Homo sapiens / KLKB1 [Homo sapiens]

Clonality

• Recombinant Monoclonal

Conjugation

Unconjugated

Type

Primary Antibodies, Biosimilars

Source

CHO cells

Field of Research

Neuroscience

Purification

>95%

Concentration

Batch dependent

Buffer

PBS buffer pH7.5

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

Fragment

IgG1-kappa

NCBI Organism

Homo sapiens

Other Product Names

X124-G01, DX-2930

Beschrijving

Lanadelumab (KLKB1) - Research Grid Biosimilar Beschikbaar in 0.1 mg. Bestel eenvoudig online met snelle levering.

Specificaties

ProductnaamLanadelumab (KLKB1) - Research Grid Biosimilar
Categorie
Beschikbare grootte0.1 mg
Catalogusnummer10-771